摘要
TP53 gene alteration confers inferior prognosis in refractory/relapse aggressive B-cell non-Hodgkin lymphoma(r/r B-NHL).From September 2016 to September 2020,257 r/r B-NHL patients were assessed for eligibility for two trials in our center,assessing anti-CD19 and anti-CD22 chimeric antigen receptor(CAR19/22)T-cell cocktail treatment alone or in combination with autologous stem cell transplantation(ASCT).TP53 alterations were screened in 123 enrolled patients and confirmed in 60.CAR19/22 T-cell administration resulted in best objective(ORR)and complete(CRR)response rate of 87.1%and 45.2%in patients with TP53 alterations.
基金
We are grateful to the faculty and staff of the Clinical and Laboratory Unit of the Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,for clinical and technical support.Wuhan BioRaid Biotechnology CO.,LTD.is acknowledged for cell manufacturing and qualitycontrol.Dr.Pengcheng Wang of Hubei Clinical Research Center for Emergency and Resuscitation,Zhongnan Hospital of Wuhan University,is appreciated for kind assistance in statistical analysis.The current project was funded by the Key Program of the National Natural Science Foundation of China(81830008 and 81630006,to Dr.J.Z.)
the National Natural Science Foundation of China(82070211 and 81670152,to Dr.L.H.,82070217 and 81873427,to Dr.J.W.,81770211 to Dr.M.X.)
the Young Topnotch Talent Cultivation Program of Hubei Province(to Dr.L.H.)and CHEN XIAO-PING Foundation for the Development of Science and Technology of Hubei Province(CXPJJH12000009-113,to Dr.J.W.).
